Journal of Parasitic Diseases: Diagnosis and Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Perspective - Journal of Parasitic Diseases: Diagnosis and Therapy (2025) Volume 10, Issue 3

Drug Resistance in Parasites: A Growing Threat to Global Health

Nisha Patel*

National Institute of Parasitic Diseases, India

Corresponding Author:
Nisha Patel
National Institute of Parasitic Diseases,
National Institute of Parasitic Diseases,
India
E-mail: nisha.patel@nips.gov.in

Received: 02-Aug-2025, Manuscript No. AAPDDT-25-166528; Editor assigned: 03-Aug-2025, AAPDDT-25-166528 (PQ); Reviewed: 17-Aug-2025, QC No. AAPDDT-25-166528; Revised: 22-Aug-2025, Manuscript No. AAPDDT-25-166528 (R); Published: 30-Aug-2025, DOI:10.35841/2591-7846.10.3.233

Citation: Patel N. Drug resistance in parasites: a growing threat to global health, J Parasit Dis Diagn Ther. 2025; 10(3):233

Introduction

Drug resistance in parasites is a mounting challenge that threatens the effectiveness of current treatment strategies for parasitic diseases. With millions of people worldwide affected by parasitic infections such as malaria, leishmaniasis, and schistosomiasis, the emergence of resistant parasite strains has serious implications for public health, particularly in resource[1]limited settings [1, 2, 3, 4].

Resistance typically arises due to the prolonged or inappropriate use of antiparasitic drugs, which exerts selective pressure on parasites, enabling the survival and proliferation of resistant variants. For example, Plasmodium falciparum, the parasite responsible for the deadliest form of malaria, has developed resistance to chloroquine, sulfadoxine[1]pyrimethamine, and, more recently, even to artemisinin-based combination therapies (ACTs) in some regions. Similarly, resistance to benzimidazoles in soil-transmitted helminths and to pentavalent antimonials in Leishmania species has been reported [5, 6].

Mechanistically, parasites develop resistance through genetic mutations, altered drug uptake or efflux, metabolic bypass, or enhanced drug detoxification. These adaptations reduce drug efficacy, complicate treatment regimens, and can lead to increased transmission and mortality. Addressing this issue requires a multipronged approach: investing in surveillance systems to detect resistance early, promoting rational drug use, developing new antiparasitic agents, and integrating alternative therapies, such as immunotherapy and vaccines. In addition, strengthening health systems and ensuring access to quality diagnostics and treatment remain vital [7, 8, 9, 10].

Conclusion

Drug resistance in parasites is an evolving threat that demands global attention and coordinated efforts. Sustained research, innovation, and policy interventions are essential to preserve the gains made in controlling parasitic diseases and to ensure effective therapies remain available for future generations.

References

  1. Schlaberg R, Chiu CY, Miller S, et al. Validation of metagenomic next-generation sequencing tests for universal pathogen detection. Arch Pathol Lab Med. 2017;141(6):776-86.

    2. Indexed at, Google Scholar, Cross Ref

  2. Fu Y, Chen Q, Xiong M, et al. Clinical performance of nanopore targeted sequencing for diagnosing infectious diseases. Microbiol Spectr. 2022;10(2):e00270-22.

    3. Indexed at, Google Scholar, Cross Ref

  3. Zamani M, Furst AL, Klapperich CM. Strategies for engineering affordable technologies for point-of-care diagnostics of infectious diseases. Acc Chem Res. 2021;54(20):3772-9.

    4. Indexed at, Google Scholar, Cross Ref

  4. Diaferio L, Giovannini M, Clark E, et al. Protocols for drug allergy desensitization in children. Expert Rev Clin Immunol. 2020;16(1):91-100.

    5. Indexed at, Google Scholar, Cross Ref

  5. de Brito Pinto TK, da Cunha-Oliveira AC, Sales-Moioli AI, et al. Clinical protocols and treatment guidelines for the management of maternal and congenital syphilis in brazil and portugal: analysis and comparisons: a narrative review. Int J Environ Res Public Health. 2022;19(17):10513.

    6. Indexed at, Google Scholar, Cross Ref 

  6. Masterson L, Moualed D, Masood A, et al. De?escalation treatment protocols for human papillomavirus?associated oropharyngeal squamous cell carcinoma. Cochrane Database Syst Rev. 2014(2).

    7. Indexed at, Google Scholar, Cross Ref

  7. Burd EM. Validation of laboratory-developed molecular assays for infectious diseases. Clin Microbiol Rev. 2010;23(3):550-76.

    8. Indexed at, Google Scholar, Cross Ref

  8. King DP, Madi M, Mioulet V, et al. New technologies to diagnose and monitor infectious diseases of livestock: challenges for sub-Saharan Africa: proceeding. Onderstepoort J Vet Res. 2012;79(2):1-6.

    9. Indexed at, Google Scholar, Cross Ref

  9. Shirlaw PJ, Chikte U, MacPhail L, et al. Oral and dental care and treatment protocols for the management of HIV?infected patients. Oral Dis. 2002;8:136-43.

    10. Indexed at, Google Scholar, Cross Ref

  10. Lagier JC, Aubry C, Delord M, et al. From expert protocols to standardized management of infectious diseases. Clin Infect Dis. 2017;65(suppl_1):S12-9.

    11. Indexed at, Google Scholar, Cross Ref

Get the App